Arabella Young, PhD

Postdoctoral Scholar
Diabetes Center
Email: 
[email protected]
Publications: 

Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors.

Annual review of medicine

Quandt Z, Young A, Perdigoto AL, Herold KC, Anderson MS

The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy.

Cancer immunology research

Young A, Quandt Z, Bluestone JA

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.

Diabetes

Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC

Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity.

Cell reports

Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M, Rosenblum MD, Van Gool F, Fong L, Bluestone JA, DuPage M

A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.

Cancer research

Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, Degli-Esposti MA, Vivier E, Waddell N, Linden J, Huntington ND, Souza-Fonseca-Guimaraes F, Smyth MJ

A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.

Cancer research

Ngiow SF, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, Smyth MJ